<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098367</article-id><article-id pub-id-type="doi">10.3389/fcvm.2025.1572096</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Triglyceride-glucose index in the prediction of acute kidney injury in patients undergoing coronary artery bypass surgery</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Chen</given-names></name><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2952313/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lv</surname><given-names>Xingping</given-names></name><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shen</surname><given-names>Yezhou</given-names></name><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Wei</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/2741203/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Tuo</given-names></name><uri xlink:href="https://loop.frontiersin.org/people/1917398/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Guoliang</given-names></name><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Feng</given-names></name><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/1671913/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff><institution>Department of Critical Care Medicine, Shanghai East Hospital, School of Medicine, Tongji University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Zenglei Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College, China</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Christian J&#x000f6;rg Rustenbach, University of T&#x000fc;bingen, Germany</p><p>Zeming Zhou, Chinese Academy of Medical Sciences and Peking Union Medical College, China</p><p>Takayuki Okada, Kansai Medical University Medical Center, Japan</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Feng Zhu <email>alexzhujunchi@hotmail.com</email></corresp><fn fn-type="equal" id="an1"><label>
<sup>&#x02020;</sup>
</label><p>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1572096</elocation-id><history><date date-type="received"><day>06</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Li, Lv, Shen, Zhou, Shen, Fan and Zhu.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Li, Lv, Shen, Zhou, Shen, Fan and Zhu</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>The triglyceride-glucose (TyG) index, indicative of insulin resistance, is recognized for predicting cardiovascular disease and metabolic disorders, notably kidney disease. In coronary artery bypass grafting (CABG) surgery, its association with postoperative renal injury is significant, suggesting its potential as a predictor for acute kidney injury (AKI) in these patients.</p></sec><sec><title>Methods</title><p>This single-center, retrospective study included 296 patients. Patients were divided into AKI and non-AKI groups postoperatively according to the KDIGO grading criteria. Multiple linear regression was employed to identify factors influencing the TyG index. Logistic regression was utilized to examine the TyG index's association with AKI in CABG patients. The TyG index's predictive power for postoperative AKI was assessed using receiver operating characteristic (ROC) curve analysis. Assessment of the Predictive Performance of the Prediction Model via Calibration plot and Clinical Decision Curve Analysis.</p></sec><sec><title>Results</title><p>In comparison between the AKI group and the non- AKI group post-CABG surgery, there was statistically significant differences in TyG index [7.53 [7.25, 7.95] vs. 6.99 [6.64, 7.39], <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05]. Logistic regression analysis indicated that for each unit increase in the TyG index, the odds of developing acute kidney injury post-CABG surgery increased by 30.573 times [odds ratio (OR)&#x02009;=&#x02009;30.573, 95% confidence interval (CI) 3.930&#x02013;237.807, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001]. The area under the curve (AUC) for the TyG index in predicting postoperative AKI in CABG patients was 0.802 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; 95% CI: 0.753&#x02013;0.851). The calibration plot of the model closely approximated the ideal diagonal line, and the clinical decision curve analysis demonstrated favorable clinical applicability.</p></sec><sec><title>Conclusion</title><p>Elevated levels of the TyG index are closely associated with the occurrence of AKI in patients following CABG surgery, and the TyG index is a potential indicator for the development of AKI post-CABG.</p></sec></abstract><kwd-group><kwd>triglyceride-glucose</kwd><kwd>metabolism</kwd><kwd>coronary artery bypass grafting (CABG)</kwd><kwd>acute kidney injury (AKI)</kwd><kwd>insulin resistance</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Peak Supporting Clinical Discipline of Shanghai Health Bureau</funding-source><award-id award-type="contract" rid="cn001">2023ZDFC0104</award-id></award-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. Grants from the Peak Supporting Clinical Discipline of Shanghai Health Bureau (2023ZDFC0104 to L.T).</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="5"/><equation-count count="0"/><ref-count count="35"/><page-count count="11"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Cardiovascular Metabolism</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Coronary artery bypass grafting (CABG) is an effective treatment method for patients with coronary heart disease (<xref rid="B1" ref-type="bibr">1</xref>). However, according to literature reports, approximately one-third of patients undergoing CABG surgery experience acute kidney injury (AKI) (<xref rid="B2" ref-type="bibr">2</xref>). Currently, clinical assessments of renal function primarily rely on creatinine levels, estimated glomerular filtration rate (eGFR), and other biochemical indicators, but these markers are not capable of providing timely warnings for the onset of AKI (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>In patients with coronary heart disease, insulin resistance is quite common and is closely associated with chronic kidney disease (<xref rid="B4" ref-type="bibr">4</xref>). Insulin resistance can lead to elevated blood glucose levels and increased serum triglyceride levels. Recent research has identified the triglyceride-glucose (TyG) index, which is derived from the logarithmic transformation of the product of plasma triglycerides and fasting blood glucose, as a potential marker for insulin resistance (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Studies have shown that an increase in the TyG index is closely related to the occurrence and progression of coronary atherosclerosis, coronary heart disease, diabetic nephropathy, and renal microvascular damage (<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>).</p><p>The TyG index has been proven to be a reliable indicator of poor prognosis in patients with kidney disease. A close association with elevated TyG index has also been found in cases of contrast-induced nephropathy (<xref rid="B12" ref-type="bibr">12</xref>). However, there are very few reports on the relationship between the TyG index and AKI following coronary artery bypass grafting. Therefore, the purpose of this study is to explore the correlation between the TyG index and AKI after CABG surgery, with the aim of providing a reference for the early prevention, monitoring, and treatment of postoperative AKI.</p></sec><sec sec-type="methods" id="s2"><label>2</label><title>Methods</title><sec id="s2a"><label>2.1</label><title>Study population</title><p>A total of 296 patients who underwent off-pump CABG surgery at the Shanghai East hospital from January 2022 to December 2023 were included in this study. The inclusion criteria were as follows: 1. Age&#x02009;&#x02265;&#x02009;18 years old with complete clinical data; 2. Underwent off-pump CABG surgery after admission. The exclusion criteria were: patients with chronic kidney disease undergoing peritoneal dialysis or hemodialysis, emergency surgery, and those with missing significant clinical data (<xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Flow diagram of patient selection.</p></caption><graphic xlink:href="fcvm-12-1572096-g001" position="float"/></fig></sec><sec id="s2b"><label>2.2</label><title>Outcomes</title><p>Based on the occurrence of AKI following surgery, participants were divided into two groups, namely the AKI group (<italic>n</italic>&#x02009;=&#x02009;132) and the non-AKI group (<italic>n</italic>&#x02009;=&#x02009;164). The preoperative, postoperative clinical data were compared. AKI was defined according to the newest consensus-based KDIGO criteria as follows: small changes in serum creatinine (&#x02265;0.3&#x02005;mg/dl or 26.5&#x02005;mmol/L) when they occurred within 48 h or a maximal change in serum creatinine &#x02265;1.5 times the baseline value until postoperative day 7 compared with preoperative baseline values or urine volume &#x0003c;0.5&#x02005;ml/kg/h for 6&#x02005;h (<xref rid="B13" ref-type="bibr">13</xref>).</p></sec><sec id="s2c"><label>2.3</label><title>Ethical statement</title><p>Approval for this study was obtained from the Committee on Ethics of Biomedical Research at Shanghai East Hospital, Tongji University School of Medicine, Shanghai (No. 2024-YS-043), with a waiver for individual patient consent granted. This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Given the observational nature of the study, informed consent of individual patient was waived by the Committee on Ethics at Shanghai East Hospital.</p></sec><sec id="s2d"><label>2.4</label><title>Data collection</title><p>Clinical data were collected from the electronic medical record system. The data included patients' general information (gender, age, height, weight), past medical history (hypertension, diabetes, coronary heart disease, heart function classification, atrial fibrillation, hyperlipidemia, myocardial infarction, chronic pulmonary disease, and chronic kidney disease), and clinical data [preoperative white blood cell count (WBC), neutrophil percentage, hemoglobin, platelets, total bilirubin, albumin, creatinine, eGFR, fasting triglycerides, fasting blood glucose, left atrial diameter, left ventricular end-diastolic diameter, left ventricular ejection fraction (LVEF), and EuroSCORE). Body Mass Index (BMI) was calculated as weight divided by the square of the patient's height, expressed in kg/m<sup>2</sup>. The measurements of triglycerides and glucose were completed under fasting conditions preoperatively. The TyG index was calculated as follows: TyG index&#x02009;=&#x02009;ln [fasting triglycerides (mg/dl)]&#x02009;&#x000d7;&#x02009;fasting blood glucose [mg/dl]/2).</p></sec><sec id="s2e"><label>2.5</label><title>Statistical analysis</title><p>This study utilized SPSS version 26.0 for statistical analysis. The Shapiro&#x02013;Wilk test was employed to assess the normality of the data. Continuous data that were normally distributed are presented as the mean&#x02009;&#x000b1;&#x02009;standard deviation, and the independent samples t-test was used to compare the means between the two groups. Continuous data not normally distributed are expressed as the median M (Q25, Q75), and the Mann&#x02013;Whitney <italic>U</italic> test was used to compare the medians between the two groups. Categorical data are represented as frequencies and percentages, and the chi-square test or Fisher's exact test was used to assess differences between groups. Pearson's correlation analysis was used to describe the association between variables and the TyG index. Logistic regression analysis was performed to identify the factors influencing the occurrence of acute kidney injury in patients after CABG surgery. The receiver operating characteristic (ROC) curve was used to determine the value of the TyG index in predicting the onset of acute kidney injury after CABG surgery, with the cutoff value derived from the Youden's index (sensitivity&#x02009;+&#x02009;specificity&#x02014;1). All tests were two-tailed, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. Subgroup analyses were performed based on age, gender, hypertension, diabetes, hyperlipidemia, myocardial infarction, chronic pulmonary disease, atrial fibrillation and chronic kidney disease to assess the prognostic utility of the TyG index across various patient subgroups. These analyses entailed stratifying patients and evaluating the performance of the TyG index in different groups to identify variations in predictive efficacy. Calibration plot were employed to evaluate the calibration performance of the model. Clinical decision curve analysis (DCA) was conducted to assess its clinical applicability.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3a"><label>3.1</label><title>Baseline characteristics</title><p>This study included a total of 296 patients who underwent CABG surgery. The baseline clinical characteristics and laboratory measurements of the patients in each group are shown in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>. Based on the occurrence of AKI following CABG, the patients were divided into two groups. Patients were stratified into acute kidney injury (AKI) groups according to serum creatinine levels, in alignment with the KDIGO clinical guidelines. There were no statistically significant differences between the groups in terms of gender, age, New York Heart Association (NYHA) classification, coronary heart disease, atrial fibrillation, hyperlipidemia, myocardial infarction, chronic pulmonary disease, preoperative neutrophil percentage, preoperative hemoglobin, preoperative platelet count, preoperative total bilirubin, preoperative albumin, preoperative left ventricular end-diastolic diameter, and preoperative creatinine levels (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). However, there were statistically significant differences in BMI, hypertension, diabetes, chronic kidney disease, EuroSCORE, preoperative WBC, preoperative left atrial diameter, preoperative LVEF, preoperative fasting triglyceride levels, preoperative fasting blood glucose, TyG index, and preoperative eGFR levels (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, as shown in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Comparison of preoperative baseline data and preoperative clinical indicators between two groups.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="center" colspan="4" rowspan="1">Overall population</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">Non-AKI Group (<italic>n</italic>&#x02009;=&#x02009;164)</th><th valign="top" align="center" rowspan="1" colspan="1">AKI Group (<italic>n</italic>&#x02009;=&#x02009;132)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">133 (81.1)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (74.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.161</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">67.00 [59.00, 73.00]</td><td valign="top" align="center" rowspan="1" colspan="1">68.00 [60.00, 75.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.304</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">23.80 [22.00, 25.70]</td><td valign="top" align="center" rowspan="1" colspan="1">24.73 [22.68, 26.75]</td><td valign="top" align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NYHA, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.952</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;I</td><td valign="top" align="center" rowspan="1" colspan="1">30 (22.6)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (19.6)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;II</td><td valign="top" align="center" rowspan="1" colspan="1">64 (48.1)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (50.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;III</td><td valign="top" align="center" rowspan="1" colspan="1">37 (27.8)</td><td valign="top" align="center" rowspan="1" colspan="1">30 (28)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IV</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (63.41)</td><td valign="top" align="center" rowspan="1" colspan="1">99 (75)</td><td valign="top" align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes mellitus, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (35.97)</td><td valign="top" align="center" rowspan="1" colspan="1">67 (50.75)</td><td valign="top" align="center" rowspan="1" colspan="1">0.013</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CAD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">160 (97.56)</td><td valign="top" align="center" rowspan="1" colspan="1">126 (95.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.350</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AF, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (3.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperlipidemia, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.526</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (13.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.266</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic lung disease, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (9.8)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (4.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.118</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic kidney disease, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Euroscore</td><td valign="top" align="center" rowspan="1" colspan="1">5.00 [3.00, 6.00]</td><td valign="top" align="center" rowspan="1" colspan="1">5.00 [4.00, 7.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.033</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">White blood cell count (x10<sup>9</sup>/L)</td><td valign="top" align="center" rowspan="1" colspan="1">6.26 [5.30, 7.53]</td><td valign="top" align="center" rowspan="1" colspan="1">6.75 [5.31, 8.18]</td><td valign="top" align="center" rowspan="1" colspan="1">0.020</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutrophil percentage (%)</td><td valign="top" align="center" rowspan="1" colspan="1">61.70 [56.25, 67.50]</td><td valign="top" align="center" rowspan="1" colspan="1">61.30 [53.40, 67.50]</td><td valign="top" align="center" rowspan="1" colspan="1">0.674</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hemoglobin (g/L)</td><td valign="top" align="center" rowspan="1" colspan="1">131.00 [119.00, 138.00]</td><td valign="top" align="center" rowspan="1" colspan="1">127.00 [113.00, 138.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.201</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Platelet (x10<sup>9</sup>/L)</td><td valign="top" align="center" rowspan="1" colspan="1">199.00 [166.00, 236.50]</td><td valign="top" align="center" rowspan="1" colspan="1">199.00 [162.00, 238.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.943</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TBil (<italic>&#x003bc;</italic>mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">11.10 [7.95, 14.65]</td><td valign="top" align="center" rowspan="1" colspan="1">10.10 [7.60, 13.60]</td><td valign="top" align="center" rowspan="1" colspan="1">0.185</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALB (mg/L)</td><td valign="top" align="center" rowspan="1" colspan="1">38.74 [37.11, 41.43]</td><td valign="top" align="center" rowspan="1" colspan="1">39.10 [37.02, 41.45]</td><td valign="top" align="center" rowspan="1" colspan="1">0.644</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAD (mm)</td><td valign="top" align="center" rowspan="1" colspan="1">37.00 [34.00, 41.00]</td><td valign="top" align="center" rowspan="1" colspan="1">39.00 [36.00, 42.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEDD (mm)</td><td valign="top" align="center" rowspan="1" colspan="1">47.00 [44.00, 50.00]</td><td valign="top" align="center" rowspan="1" colspan="1">48.00 [44.00, 52.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.265</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEF (%)</td><td valign="top" align="center" rowspan="1" colspan="1">63.00 [54.50, 67.00]</td><td valign="top" align="center" rowspan="1" colspan="1">60.00 [49.00, 65.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.006</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">1.17 [0.97, 1.60]</td><td valign="top" align="center" rowspan="1" colspan="1">1.68 [1.37, 2.42]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FBG (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">5.40 [4.74, 6.30]</td><td valign="top" align="center" rowspan="1" colspan="1">6.50 [5.10, 8.61]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TyG Index</td><td valign="top" align="center" rowspan="1" colspan="1">6.99 [6.64, 7.39]</td><td valign="top" align="center" rowspan="1" colspan="1">7.53 [7.25, 7.95]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crea (&#x003bc;mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">72.00 [70.50, 88.00]</td><td valign="top" align="center" rowspan="1" colspan="1">101.90 [91.25, 117.50]</td><td valign="top" align="center" rowspan="1" colspan="1">0.187</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (ml/min)</td><td valign="top" align="center" rowspan="1" colspan="1">87.00 [75.00, 105.00]</td><td valign="top" align="center" rowspan="1" colspan="1">69.46 [51.00, 76.25]</td><td valign="top" align="center" rowspan="1" colspan="1">0.014</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>Data are expressed as the median (25th&#x02013;75th percentiles), or number (percentage). BMI, body mass index; CAD, coronary heart disease; AF, atrial fibrillation; MI, myocardial infarction; TBiL, total bilirubin; Alb,albumin; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; TG, triglyceride; FBG, fasting blood-glucose; TyG index, triglyceride-glucose index; Crea, creatinine; eGFR, estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap><p>The postoperative laboratory measurements for patients in each group are presented in <xref rid="T2" ref-type="table">Table&#x000a0;2</xref>. There were no statistically significant differences between the groups in terms of mechanical ventilation time, total hospital stay, the number of bypass grafts, operative time and the eGFR levels on the day of surgery (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). However, statistically significant differences were observed when comparing ICU stay duration, creatinine levels on the day of surgery, creatinine and eGFR levels on the first postoperative day, creatinine and eGFR levels on the second postoperative day, and creatinine and eGFR levels on the third postoperative day (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, as shown in <xref rid="T2" ref-type="table">Table&#x000a0;2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Comparison of postoperative clinical indicators between two groups.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="center" colspan="4" rowspan="1">Overall population</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Variable</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">Non-AKI Group (<italic>n</italic>&#x02009;=&#x02009;164)</th><th valign="top" align="center" rowspan="1" colspan="1">AKI Group (<italic>n</italic>&#x02009;=&#x02009;132)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of grafts, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.152</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;I</td><td valign="top" align="center" rowspan="1" colspan="1">38 (23.2)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (16.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;II</td><td valign="top" align="center" rowspan="1" colspan="1">120 (73.2)</td><td valign="top" align="center" rowspan="1" colspan="1">109 (82.6)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;III</td><td valign="top" align="center" rowspan="1" colspan="1">6 (3.7)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Operative time (minutes)</td><td valign="top" align="center" rowspan="1" colspan="1">200.00 [168.75, 252.50]</td><td valign="top" align="center" rowspan="1" colspan="1">210.00 [150.00, 240.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.562</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ICU length of stay (minutes)</td><td valign="top" align="center" rowspan="1" colspan="1">1404.00 [1238.00, 2745.00]</td><td valign="top" align="center" rowspan="1" colspan="1">1693.00 [1371.75, 2940.50]</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mechanical ventilation (minutes)</td><td valign="top" align="center" rowspan="1" colspan="1">317.00 [224.00, 487.00]</td><td valign="top" align="center" rowspan="1" colspan="1">347.00 [249.00, 569.75]</td><td valign="top" align="center" rowspan="1" colspan="1">0.140</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">hospital length of stay (days)</td><td valign="top" align="center" rowspan="1" colspan="1">15.00 [13.00, 19.00]</td><td valign="top" align="center" rowspan="1" colspan="1">16.00 [14.00, 19.25]</td><td valign="top" align="center" rowspan="1" colspan="1">0.083</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crea (D1) (&#x003bc;mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">88.50[68.00,104.75]</td><td valign="top" align="center" rowspan="1" colspan="1">96.00 [79.25, 163.25]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (D1) (ml/min)</td><td valign="top" align="center" rowspan="1" colspan="1">76.50 [64.00, 110.26]</td><td valign="top" align="center" rowspan="1" colspan="1">58.50 [36.25, 89.25]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crea (D2) (&#x003bc;mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">82.00 [61.75, 101.25]</td><td valign="top" align="center" rowspan="1" colspan="1">111.50 [76.75, 162.75]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (D2) (ml/min)</td><td valign="top" align="center" rowspan="1" colspan="1">79.00 [54.25, 115.25]</td><td valign="top" align="center" rowspan="1" colspan="1">57.00 [32.00, 88.50]</td><td valign="top" align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crea (D3) (&#x003bc;mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">74.50 [68.50, 96.60]</td><td valign="top" align="center" rowspan="1" colspan="1">104.50 [77.50, 148.00]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (D3) (ml/min)</td><td valign="top" align="center" rowspan="1" colspan="1">95.56 [70.00, 111.00]</td><td valign="top" align="center" rowspan="1" colspan="1">52.50 [37.25, 86.25]</td><td valign="top" align="center" rowspan="1" colspan="1">0.015</td></tr></tbody></table><table-wrap-foot><fn id="table-fn2"><p>Data are expressed as the median (25th&#x02013;75th percentiles). D0, the day after surgery; D1, the first day after surgery; D2, the second day after surgery; D3 the third day after surgery; Crea, creatinine; eGFR, estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><label>3.2</label><title>Correlation between TyG Index and baseline data</title><p>Pearson's or Spearman's rank correlation analysis was performed to explore the relationship between TyG index and clinical baseline data. As presented in <xref rid="T3" ref-type="table">Table&#x000a0;3</xref>, the TyG index was positively correlated with Hypertension as well as Diabetes mellitus, BMI, Chronic kidney disease, ICU length of stay, and Preoperative WBC levels and negatively correlated with Preoperative eGFR and LVEF (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Correlation between TyG index and potential risk factors.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">Correlation coefficient (r)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension</td><td valign="top" align="center" rowspan="1" colspan="1">0.127</td><td valign="top" align="center" rowspan="1" colspan="1">0.029</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td valign="top" align="center" rowspan="1" colspan="1">0.282</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI</td><td valign="top" align="center" rowspan="1" colspan="1">0.143</td><td valign="top" align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEF</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.176</td><td valign="top" align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic kidney disease</td><td valign="top" align="center" rowspan="1" colspan="1">0.047</td><td valign="top" align="center" rowspan="1" colspan="1">0.423</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EuroSCORE</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.028</td><td valign="top" align="center" rowspan="1" colspan="1">0.629</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperative WBC</td><td valign="top" align="center" rowspan="1" colspan="1">0.127</td><td valign="top" align="center" rowspan="1" colspan="1">0.029</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperative LAD</td><td valign="top" align="center" rowspan="1" colspan="1">0.017</td><td valign="top" align="center" rowspan="1" colspan="1">0.773</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperative eGFR</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.115</td><td valign="top" align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ICU length of stay</td><td valign="top" align="center" rowspan="1" colspan="1">0.149</td><td valign="top" align="center" rowspan="1" colspan="1">0.010</td></tr></tbody></table><table-wrap-foot><fn id="table-fn3"><p>BMI, body mass index; LVEF, left ventricular ejection fraction; WBC White blood cell count; LAD, left atrial diameter; eGFR, estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><label>3.3</label><title>Risk factors for AKI after CABG</title><p>Logistic regression analysis revealed that ICU stay duration [OR&#x02009;=&#x02009;1, 95% CI (1.000, 1.001), <italic>P</italic>&#x02009;=&#x02009;0.036], and the TyG index [OR&#x02009;=&#x02009;30.573, 95% CI (3.930, 237.807), <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001] are risk factors for the development of acute kidney injury in patients after CABG surgery (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, see <xref rid="T4" ref-type="table">Table&#x000a0;4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Logistic regression analysis of AKI in patients.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
</th><th valign="top" align="center" rowspan="1" colspan="1">SE</th><th valign="top" align="center" rowspan="1" colspan="1">Wald <italic>X</italic><sup>2</sup> value</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th><th valign="top" align="center" rowspan="1" colspan="1">OR value</th><th valign="top" align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.227</td><td valign="top" align="center" rowspan="1" colspan="1">0.625</td><td valign="top" align="center" rowspan="1" colspan="1">3.849</td><td valign="top" align="center" rowspan="1" colspan="1">0.050</td><td valign="top" align="center" rowspan="1" colspan="1">0.293</td><td valign="top" align="center" rowspan="1" colspan="1">(0.086 0.999)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.356</td><td valign="top" align="center" rowspan="1" colspan="1">0.643</td><td valign="top" align="center" rowspan="1" colspan="1">0.307</td><td valign="top" align="center" rowspan="1" colspan="1">0.580</td><td valign="top" align="center" rowspan="1" colspan="1">0.701</td><td valign="top" align="center" rowspan="1" colspan="1">(0.199 2.468)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic kidney disease</td><td valign="top" align="center" rowspan="1" colspan="1">3.399</td><td valign="top" align="center" rowspan="1" colspan="1">1.974</td><td valign="top" align="center" rowspan="1" colspan="1">2.965</td><td valign="top" align="center" rowspan="1" colspan="1">0.085</td><td valign="top" align="center" rowspan="1" colspan="1">29.927</td><td valign="top" align="center" rowspan="1" colspan="1">(0.625 1432.998)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI</td><td valign="top" align="center" rowspan="1" colspan="1">0.085</td><td valign="top" align="center" rowspan="1" colspan="1">0.096</td><td valign="top" align="center" rowspan="1" colspan="1">0.784</td><td valign="top" align="center" rowspan="1" colspan="1">0.376</td><td valign="top" align="center" rowspan="1" colspan="1">1.089</td><td valign="top" align="center" rowspan="1" colspan="1">(0.902 1.315)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ICU length of stay</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">4.380</td><td valign="top" align="center" rowspan="1" colspan="1">0.036</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">(1.000 1.001)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EuroSCORE</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.051</td><td valign="top" align="center" rowspan="1" colspan="1">0.187</td><td valign="top" align="center" rowspan="1" colspan="1">0.073</td><td valign="top" align="center" rowspan="1" colspan="1">0.787</td><td valign="top" align="center" rowspan="1" colspan="1">0.951</td><td valign="top" align="center" rowspan="1" colspan="1">(0.659 1.372)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperative WBC</td><td valign="top" align="center" rowspan="1" colspan="1">0.137</td><td valign="top" align="center" rowspan="1" colspan="1">0.116</td><td valign="top" align="center" rowspan="1" colspan="1">1.397</td><td valign="top" align="center" rowspan="1" colspan="1">0.237</td><td valign="top" align="center" rowspan="1" colspan="1">1.146</td><td valign="top" align="center" rowspan="1" colspan="1">(0.914 1.438)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperative LAD</td><td valign="top" align="center" rowspan="1" colspan="1">0.062</td><td valign="top" align="center" rowspan="1" colspan="1">0.056</td><td valign="top" align="center" rowspan="1" colspan="1">1.244</td><td valign="top" align="center" rowspan="1" colspan="1">0.265</td><td valign="top" align="center" rowspan="1" colspan="1">1.064</td><td valign="top" align="center" rowspan="1" colspan="1">(0.954 1.187)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEF</td><td valign="top" align="center" rowspan="1" colspan="1">0.013</td><td valign="top" align="center" rowspan="1" colspan="1">0.028</td><td valign="top" align="center" rowspan="1" colspan="1">0.232</td><td valign="top" align="center" rowspan="1" colspan="1">0.630</td><td valign="top" align="center" rowspan="1" colspan="1">1.014</td><td valign="top" align="center" rowspan="1" colspan="1">(0.960 1.070)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Preoperative eGFR</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.029</td><td valign="top" align="center" rowspan="1" colspan="1">0.034</td><td valign="top" align="center" rowspan="1" colspan="1">0.730</td><td valign="top" align="center" rowspan="1" colspan="1">0.393</td><td valign="top" align="center" rowspan="1" colspan="1">0.971</td><td valign="top" align="center" rowspan="1" colspan="1">(0.908 1.039)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TyG Index</td><td valign="top" align="center" rowspan="1" colspan="1">3.420</td><td valign="top" align="center" rowspan="1" colspan="1">1.047</td><td valign="top" align="center" rowspan="1" colspan="1">10.678</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">30.573</td><td valign="top" align="center" rowspan="1" colspan="1">(3.930 237.807)</td></tr></tbody></table><table-wrap-foot><fn id="table-fn4"><p>BMI, body mass index; LVEF, left ventricular ejection fraction; WBC White blood cell count; LAD, left atrial diameter; eGFR, estimated glomerular filtration rate; TyG index, triglyceride-glucose index.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><label>3.4</label><title>Tyg index for AKI</title><p>Further analysis involved the construction of a receiver operating characteristic (ROC) curve for the TyG index to predict the occurrence of AKI in patients after CABG surgery. The results indicated that the area under the ROC curve (AUC) for the TyG index in predicting postoperative AKI in CABG patients was 0.802 (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; 95% CI 0.753&#x02013;0.851). At a TyG index threshold of 7.20, the Youden's index was 0.506, Positive Predictive Value was 0.6815287, Negative Predictive Value was 0.8201439, with a sensitivity of 81.1% and a specificity of 69.5% (<xref rid="F2" ref-type="fig">Figure&#x000a0;2</xref>). Compare the baseline characteristics of the two groups, and determine if there are statistically significant differences in gender, history of diabetes, Euroscore, preoperative total bilirubin, preoperative LVEF, preoperative fasting triglyceride levels, preoperative fasting blood glucose, and the incidence of AKI between the groups (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, see <xref rid="T5" ref-type="table">Table&#x000a0;5</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>The ROC curve of TyG index for predicting AKI.</p></caption><graphic xlink:href="fcvm-12-1572096-g002" position="float"/></fig><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Comparison of preoperative baseline data and preoperative clinical indicators between two groups.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="center" colspan="4" rowspan="1">Overall population</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">TyG index&#x02009;&#x0003c;&#x02009;7.20 (<italic>n</italic>&#x02009;=&#x02009;139)</th><th valign="top" align="center" rowspan="1" colspan="1">TyG inde&#x02009;x&#x02265;&#x02009;7.20 (<italic>n</italic>&#x02009;=&#x02009;157)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">116 (83.45)</td><td valign="top" align="center" rowspan="1" colspan="1">115 (73.25)</td><td valign="top" align="center" rowspan="1" colspan="1">0.036</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">67.00 [60.00, 73.00]</td><td valign="top" align="center" rowspan="1" colspan="1">67.00 [57.00, 74.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.588</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI [median(IQR)]</td><td valign="top" align="center" rowspan="1" colspan="1">23.80&#x02009;&#x000b1;&#x02009;2.98</td><td valign="top" align="center" rowspan="1" colspan="1">24.49&#x02009;&#x000b1;&#x02009;3.08</td><td valign="top" align="center" rowspan="1" colspan="1">0.092</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NYHA, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.764</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;I</td><td valign="top" align="center" rowspan="1" colspan="1">25 (23.10)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (19.7)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;II</td><td valign="top" align="center" rowspan="1" colspan="1">49 (45.40)</td><td valign="top" align="center" rowspan="1" colspan="1">69 (52.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;III</td><td valign="top" align="center" rowspan="1" colspan="1">32 (29.60)</td><td valign="top" align="center" rowspan="1" colspan="1">35 (26.50)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IV</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.90)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1.50)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (63.41)</td><td valign="top" align="center" rowspan="1" colspan="1">99 (75)</td><td valign="top" align="center" rowspan="1" colspan="1">0.078</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes mellitus, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (28.78)</td><td valign="top" align="center" rowspan="1" colspan="1">86 (54.78)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CAD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">133 (95.68)</td><td valign="top" align="center" rowspan="1" colspan="1">153 (97.45)</td><td valign="top" align="center" rowspan="1" colspan="1">0.524</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AF, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (5.76)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2.55)</td><td valign="top" align="center" rowspan="1" colspan="1">0.238</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hyperlipidemia, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (7.19)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (8.92)</td><td valign="top" align="center" rowspan="1" colspan="1">0.672</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (9.35)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (12.74)</td><td valign="top" align="center" rowspan="1" colspan="1">0.460</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic lung disease, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (7.19)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (7.64)</td><td valign="top" align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic kidney disease, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2.88)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (6.37)</td><td valign="top" align="center" rowspan="1" colspan="1">0.181</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Euroscore</td><td valign="top" align="center" rowspan="1" colspan="1">5.00 [4.00, 7.00]</td><td valign="top" align="center" rowspan="1" colspan="1">5.00 [4.00, 7.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.033</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">White blood cell count (x10<sup>9</sup>/L)</td><td valign="top" align="center" rowspan="1" colspan="1">6.32 [5.17, 7.57]</td><td valign="top" align="center" rowspan="1" colspan="1">6.54 [5.36, 7.98]</td><td valign="top" align="center" rowspan="1" colspan="1">0.060</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutrophil percentage (%)</td><td valign="top" align="center" rowspan="1" colspan="1">61.70 [55.90, 67.20]</td><td valign="top" align="center" rowspan="1" colspan="1">61.30 [53.70, 67.50]</td><td valign="top" align="center" rowspan="1" colspan="1">0.647</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hemoglobin (g/L)</td><td valign="top" align="center" rowspan="1" colspan="1">129.00 [118.00, 136.00]</td><td valign="top" align="center" rowspan="1" colspan="1">127.54&#x02009;&#x000b1;&#x02009;17.31</td><td valign="top" align="center" rowspan="1" colspan="1">0.845</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Platelet (x10<sup>9</sup>/L)</td><td valign="top" align="center" rowspan="1" colspan="1">195.00 [164.50, 234.50]</td><td valign="top" align="center" rowspan="1" colspan="1">200.00 [165.00, 238.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.514</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TBil (&#x003bc;mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">11.60 [8.05, 14.40]</td><td valign="top" align="center" rowspan="1" colspan="1">9.55 [7.57, 13.05]</td><td valign="top" align="center" rowspan="1" colspan="1">0.014</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALB (g/L)</td><td valign="top" align="center" rowspan="1" colspan="1">38.92&#x02009;&#x000b1;&#x02009;3.15</td><td valign="top" align="center" rowspan="1" colspan="1">39.52 [37.14, 41.92]</td><td valign="top" align="center" rowspan="1" colspan="1">0.169</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAD (mm)</td><td valign="top" align="center" rowspan="1" colspan="1">37.90&#x02009;&#x000b1;&#x02009;5.40</td><td valign="top" align="center" rowspan="1" colspan="1">38.00 [36.00, 41.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.241</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEDD (mm)</td><td valign="top" align="center" rowspan="1" colspan="1">47.00 [44.00, 50.00]</td><td valign="top" align="center" rowspan="1" colspan="1">47.00 [43.00, 51.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.937</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LVEF (%)</td><td valign="top" align="center" rowspan="1" colspan="1">63.50 [56.00, 66.25]</td><td valign="top" align="center" rowspan="1" colspan="1">60.00 [49.00, 65.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.024</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">1.11 [0.89, 1.36]</td><td valign="top" align="center" rowspan="1" colspan="1">1.88 [1.45, 2.41]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FBG (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">5.02 [4.50, 5.72]</td><td valign="top" align="center" rowspan="1" colspan="1">6.87 [5.50, 8.80]</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crea (&#x003bc;mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">80.40 [69.15, 93.70]</td><td valign="top" align="center" rowspan="1" colspan="1">84.60 [67.60, 101.00]</td><td valign="top" align="center" rowspan="1" colspan="1">0.127</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (ml/min)</td><td valign="top" align="center" rowspan="1" colspan="1">77.57&#x02009;&#x000b1;&#x02009;16.71</td><td valign="top" align="center" rowspan="1" colspan="1">72.17&#x02009;&#x000b1;&#x02009;21.70</td><td valign="top" align="center" rowspan="1" colspan="1">0.199</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AKI</td><td valign="top" align="center" rowspan="1" colspan="1">25 (17.99)</td><td valign="top" align="center" rowspan="1" colspan="1">107 (68.15)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="table-fn5"><p>Data are expressed as the median (25th&#x02013;75th percentiles), mean&#x02009;&#x000b1;&#x02009;standard deviation, or number (percentage). BMI, body mass index; CAD, coronary heart disease; AF, atrial fibrillation; MI, myocardial infarction; TBiL, total bilirubin; Alb, albumin; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; TG, triglyceride;FBG, fasting blood-glucose; TyG index, triglyceride-glucose index; Crea, creatinine; eGFR, estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><label>3.5</label><title>Calibration and clinical applicability analysis of the model</title><p>Validation of the TyG prediction model calibration was performed (<xref rid="F3" ref-type="fig">Figure&#x000a0;3</xref>), with the calibrated curve closely aligning with the reference line, indicating good calibration performance. Decision curve analysis (DCA) was conducted (<xref rid="F4" ref-type="fig">Figure&#x000a0;4</xref>), demonstrating a high net benefit when using this model to predict the occurrence of AKI in patients after CABG surgery at threshold probabilities ranging from 10% to 90%.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Calibration plot of the prediction model.</p></caption><graphic xlink:href="fcvm-12-1572096-g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Decision curve analysis of the prediction model.</p></caption><graphic xlink:href="fcvm-12-1572096-g004" position="float"/></fig></sec><sec id="s3f"><label>3.6</label><title>Line chart of creatinine changes</title><p>Compared to preoperative levels, creatinine exhibited an increasing trend postoperatively. However, pre-discharge creatinine levels showed a declining trend compared to postoperative values. This pattern was consistent in both the AKI and non-AKI groups, with pre-discharge creatinine levels decreasing relative to postoperative measurements in all patients (<xref rid="F5" ref-type="fig">Figure&#x000a0;5</xref>).</p><fig position="float" id="F5"><label>Figure 5</label><caption><p>Line chart of patients' creatinine changes. Cr1, preoperative creatinine; Cr2, postoperative Day0 creatinine; Cr3, postoperative Day1 creatinine; Cr4, pre-discharge creatinine.</p></caption><graphic xlink:href="fcvm-12-1572096-g005" position="float"/></fig></sec><sec id="s3g"><label>3.7</label><title>Subgroup analysis</title><p>Subgroup analyses confirmed the prognostic value of the TyG index across diverse patient characteristics. When stratified by sex (groups 0 and 1), group 0 exhibited an event rate of 18.79 (95% CI: 4.66&#x02013;75.80, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), whereas group 1 showed an event rate of 7.75 (95% CI: 4.25&#x02013;14.13, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), with an interaction <italic>P</italic>-value of 0.253, indicating no significant sex-based effect. For age stratification (groups 0 and 1), group 0 had an event rate of 17.17 (95% CI: 5.99&#x02013;49.19, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), and group 1 demonstrated an event rate of 7.28 (95% CI: 3.74&#x02013;14.17, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), with an interaction <italic>P</italic>-value of 0.177, suggesting no age-related modification. In hypertension subgroups, non-hypertensive patients had an event rate of 7.90 (95% CI: 2.98&#x02013;20.94, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), compared to 9.51 (95% CI: 4.91&#x02013;18.44, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) in hypertensive patients, with an interaction <italic>P</italic>-value of 0.758. For diabetes stratification, non-diabetic patients exhibited an event rate of 6.50 (95% CI: 3.28&#x02013;12.89, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), whereas diabetic patients showed a significantly higher rate of 16.86 (95% CI: 5.92&#x02013;48.06, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), though the interaction <italic>P</italic>-value was 0.135. In hyperlipidemia subgroups, non-hyperlipidemic patients had an event rate of 9.51 (95% CI: 4.91&#x02013;18.44, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), vs. 4.00 (95% CI: 0.62&#x02013;25.96, <italic>P</italic>&#x02009;=&#x02009;0.146) in hyperlipidemic patients, with an interaction <italic>P</italic>-value of 0.356. Myocardial infarction (MI) subgroups showed event rates of 9.08 (95% CI: 5.08&#x02013;16.20, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) for non-MI patients and 10.00 (95% CI: 1.94&#x02013;51.54, <italic>P</italic>&#x02009;=&#x02009;0.006) for MI patients (interaction <italic>P</italic>&#x02009;=&#x02009;0.913). For chronic pulmonary disease, non-affected patients had an event rate of 9.73 (95% CI: 5.52&#x02013;17.13, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), compared to 6.43 (95% CI: 0.61&#x02013;68.30, <italic>P</italic>&#x02009;=&#x02009;0.123) in affected patients (interaction <italic>P</italic>&#x02009;=&#x02009;0.738). Lastly, in atrial fibrillation subgroups, non-affected patients exhibited an event rate of 9.40 (95% CI: 5.36&#x02013;16.48, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001), vs. 9.00 (95% CI: 0.56&#x02013;143.89, <italic>P</italic>&#x02009;=&#x02009;0.120) in affected patients (interaction <italic>P</italic>&#x02009;=&#x02009;0.976) (<xref rid="F6" ref-type="fig">Figure&#x000a0;6</xref>).</p><fig position="float" id="F6"><label>Figure 6</label><caption><p>Subgroup Analysis of patients.</p></caption><graphic xlink:href="fcvm-12-1572096-g006" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>This study explored the relationship between the TyG index and the occurrence of AKI in patients after CABG surgery. The results of the multiple linear regression analysis indicated that the level of the TyG index is a significant influencing factor on the risk of AKI. Logistic regression analysis showed that patients with an elevated TyG index had a higher relative risk of renal dysfunction, suggesting an elevated TyG index having a predictive role for early renal injury in patients following off-pump CABG.</p><p>Insulin resistance, which is a condition affecting the body's overall ability to process glucose and lipids, is defined by the presence of elevated insulin levels (hyperinsulinemia), high blood sugar (hyperglycemia), and increased blood lipids (hyperlipidemia). Research has indicated that high blood sugar levels independently forecast the risk of developing AKI (<xref rid="B14" ref-type="bibr">14</xref>). Hyperglycemia can lead to disruptions in the kidney's blood flow and the permeability of its blood vessels. This can result in a series of complications such as the obstruction of capillaries, hypoxia, and glomerulosclerosis. These changes can contribute to the leakage of proteins into the urine (proteinuria) and potentially trigger AKI (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Additionally, dyslipidemia has been proven to be crucial in the development and progression of kidney disease (<xref rid="B17" ref-type="bibr">17</xref>). Although the mechanisms by which lipids damage renal vasculature, mesangial cells, and tubular cells are not yet fully understood, Moorhead first proposed the &#x0201c;lipotoxicity hypothesis&#x0201d; (<xref rid="B18" ref-type="bibr">18</xref>). Current research indicates that hypertriglyceridemia is an independent risk factor for early AKI (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>Insulin resistance is a pivotal determinant in the etiology of cardiovascular diseases, diabetes mellitus, and renal impairment. The hormone insulin, through its distinct regulatory influence on metabolic and proliferative pathways within the kidney, modulates renal microcirculatory dynamics. This intricate interplay is essential for the kidney's homeostatic balance and its ability to manage fluid and electrolyte equilibrium (<xref rid="B20" ref-type="bibr">20</xref>). Insulin resistance often impairs renal blood flow and glomerular filtration, which may lead to issues such as inflammation and fibrosis (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B20" ref-type="bibr">20</xref>). Insulin resistance is a common comorbidity in individuals presenting with renal impairment, irrespective of their diabetic status. It is imperative to acknowledge that insulin resistance stands as a significant and autonomous predictor of renal pathology, underscoring its relevance in the pathogenesis of kidney disorders (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). The euglycemic clamp technique is considered the criterion standard for evaluating insulin resistance, providing a measure of glucose metabolism rate via intravenous glucose infusion. Despite its accuracy, the technique's invasiveness and the associated economic burden constrain its routine use in clinical settings (<xref rid="B23" ref-type="bibr">23</xref>). The TyG index, a surrogate marker derived from fasting triglycerides and glucose, is widely used to assess insulin resistance. However, it is not a direct measure like the gold-standard hyperinsulinemic euglycemic clamp. The TyG index may be influenced by other metabolic factors, such as inflammation and fat distribution. Despite these limitations, it is valuable in large-scale studies and clinical practice due to its simplicity. In this study, it was observed that patients who developed AKI postoperatively had higher BMI values and a higher proportion of past medical histories of hypertension, diabetes, and chronic kidney disease, which is consistent with the findings of the aforementioned studies indicating that such patients are more prone to insulin resistance.</p><p>The TyG index, derived from fasting blood glucose and fasting triglycerides, is a reliable surrogate marker for insulin resistance. The TyG index has gained recognition as a pivotal prognostic marker for diabetes and atherosclerosis. Additionally, it demonstrates a strong correlation with proteinuria and the deterioration of renal function, highlighting its utility in the clinical assessment of metabolic and renal health (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B24" ref-type="bibr">24</xref>). Studies on renal impairment in elderly patients have demonstrated a positive and independent relationship between the TyG index and the deterioration of kidney function (<xref rid="B25" ref-type="bibr">25</xref>).</p><p>Studies have reported that the TyG index can effectively predict the onset and progression of diabetic nephropathy and chronic kidney disease. The kidney, being among the organs that are responsive to insulin, houses an array of cells that are sensitive to this hormone and exerts a distinctive function within the renal system. These functions include the regulation of glomerular filtration rate, the preservation of tubular sodium equilibrium, and the modulation of gluconeogenesis, thereby underscoring the kidney's integral role in both metabolic and excretory processes. If insulin resistance occurs, the insulin signaling pathway is impaired, leading to renal damage (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B26" ref-type="bibr">26</xref>).</p><p>AKI is one of the most common postoperative complications in patients undergoing cardiac surgery. Additionally, AKI has an adverse impact on patient prognosis (<xref rid="B27" ref-type="bibr">27</xref>). According to various studies, the incidence rate ranges from 15% to 30%, depending on the type of surgery (<xref rid="B28" ref-type="bibr">28</xref>). Among these patients with AKI, approximately 2% to 5% require hemodialysis treatment, which significantly affects the morbidity, mortality, and hospitalization costs for surgical patients (<xref rid="B28" ref-type="bibr">28</xref>). It is important to recognize that AKI in the context of cardiac surgery is a multifaceted event that can manifest at various stages. It may arise during the preoperative preparation phase, continue to occur intraoperatively, and persist into the postoperative recovery period. This underscores the need for vigilant monitoring and proactive management of renal function throughout the entire perioperative course (<xref rid="B29" ref-type="bibr">29</xref>). AKI related to cardiac surgery leads to prolonged hospital stays, increased hospitalization costs, and a higher mortality rate. Early diagnosis and guidance for the protection of renal function are crucial. Historically, renal health has been gauged primarily through biochemical indicators such as serum creatinine and blood urea nitrogen. However, these markers have limitations in their sensitivity to detecting acute or short-term fluctuations in kidney function. Their delayed response to renal impairment makes them less than ideal for early detection of changes, particularly in settings where rapid assessment is crucial, such as in intensive care or following major surgery (<xref rid="B30" ref-type="bibr">30</xref>).</p><p>The increase in creatinine levels can only be observed several days after renal injury, which may lead to an underestimation of the incidence of acute kidney injury (<xref rid="B31" ref-type="bibr">31</xref>). Markers such as Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) have drawbacks including low sensitivity and poor specificity, which prevent their widespread use in clinical practice (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Therefore, the relationship between the TyG index and AKI following cardiac surgery is imperative to explore. Previous studies have reported that the TyG index is significantly associated with a decrease in eGFR and diabetic nephropathy. However, the relationship between the TyG index and AKI after cardiac surgery has not yet been investigated. This study shows that patients who developed AKI postoperatively had a longer ICU stay, and both postoperative creatinine levels and eGFR were worse to varying degrees compared to preoperative levels, similar to the results of previous studies. The TyG index in patients who developed AKI after CABG surgery was significantly higher than in those who did not, indicating that the TyG index is a risk factor for the occurrence of postoperative acute kidney injury. The results of the ROC curve analysis suggest that the TyG index has some value in predicting the occurrence of acute kidney injury in patients after CABG surgery. The calibration plot demonstrated good predictive accuracy, and the clinical decision curve analysis (DCA) indicated favorable clinical applicability.</p><p>This study categorized patients into two groups based on the cut-off value from the ROC curve: one with a TyG index less than 7.20 and the other with a TyG index greater than 7.20. It was observed that there were more female patients in the group with a higher TyG index, and these patients were more likely to have comorbidities such as diabetes, hyperlipidemia, and hyperglycemia preoperatively. Assessments using the Euroscore and LVEF indicated that patients with higher TyG indices also had relatively higher surgical risks and poorer preoperative left cardiac function. Patients with elevated TyG indices had lower preoperative total bilirubin levels, which may be due to the association of high TyG index with non-alcoholic fatty liver disease, showing a negative correlation with bilirubin (<xref rid="B34" ref-type="bibr">34</xref>). Elevated levels of the TyG are significantly correlated with an increased propensity for the progression of non-alcoholic fatty liver disease (NAFLD) and a concomitant reduction in the likelihood of its remission. Elevation of serum total bilirubin has been found to be negatively correlated with the prevalence of NAFLD (<xref rid="B35" ref-type="bibr">35</xref>). Additionally, the risk of developing AKI was higher in patients with a high TyG index.</p><p>Based on the above data, the TyG index appears to be a highly reliable and effective indicator for predicting the incidence of AKI. Subgroup analyses showed that, though numerical risk ratio variations existed across subgroups, patient characteristics did not alter the TyG index-outcome association. The TyG index maintained consistent predictive accuracy in all subgroups, supporting its reliability as an AKI risk stratification tool independent of patient features. Our study results indicate a close correlation between elevated TyG levels and an increased incidence of AKI. AKI can ultimately lead to chronic kidney disease, uremia, or death. Our findings can assist in the clinical identification of high-risk patients and in taking preventive measures to avert the development of AKI. To date, clinical studies on the relationship between AKI and the TyG marker in patients following cardiac surgery have been limited. Our investigation fills this gap.</p></sec><sec id="s5"><label>5</label><title>Limitations</title><p>This study has certain limitations. Firstly, the results were obtained from a single center, retrospective study, and selection bias is inevitable. This study was limited by a relatively small sample size, which may result in insufficient statistical power. Secondly, we only measured fasting triglycerides and fasting blood glucose upon admission, and these parameters were not continuously measured. This is a retrospective study, and due to incomplete 24&#x02005;h urine output data, the diagnosis of acute kidney injury primarily relied on serum creatinine levels, potentially omitting patients with AKI identified by reduced urine output. Thirdly, we were only able to demonstrate a correlation between the TyG index and early renal injury in patients following off-pump CABG surgery, but the existence of a causal relationship would require further prospective studies to confirm.</p></sec><sec sec-type="conclusions" id="s6"><label>6</label><title>Conclusion</title><p>The results of this study indicate that the TyG index is positively correlated with the occurrence of AKI following cardiac surgery. Elevated TyG levels are closely associated with an increased incidence of AKI, suggesting that the TyG index may be a valuable indicator for assessing the risk of AKI in patients after cardiac surgery. This finding offers new possibilities for the clinical identification of high-risk patient groups, and for the prevention and early intervention of AKI. However, further research is needed to validate the accuracy and reliability of the TyG index in predicting AKI after cardiac surgery.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank Dr. Zhang Haitao from Department of Critical Care Medicine, Shanghai East Hospital for his help in polishing our paper.</p></ack><sec sec-type="data-availability" id="s7"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s8"><title>Ethics statement</title><p>The studies involving humans were approved by Committee on Ethics of Biomedical Research at Shanghai East Hospital, Tongji University School of Medicine, Shanghai. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from primarily isolated as part of your previous study for which ethical approval was obtained. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="s9"><title>Author contributions</title><p>CL: Writing &#x02013; original draft. XL: Writing &#x02013; original draft. YS: Writing &#x02013; original draft. WZ: Writing &#x02013; original draft. TS: Writing &#x02013; original draft. GF: Writing &#x02013; original draft. FZ: Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s11"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s12"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s13"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>F-J</given-names></name><name><surname>Sousa-Uva</surname><given-names>M</given-names></name><name><surname>Ahlsson</surname><given-names>A</given-names></name><name><surname>Alfonso</surname><given-names>F</given-names></name><name><surname>Banning</surname><given-names>AP</given-names></name><name><surname>Benedetto</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>2018 ESC/EACTS guidelines on myocardial revascularization</article-title>. <source>Eur Heart J</source>. (<year>2019</year>) <volume>40</volume>(<issue>2</issue>):<fpage>87</fpage>&#x02013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehy394</pub-id><pub-id pub-id-type="pmid">30165437</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosner</surname><given-names>MH</given-names></name><name><surname>Okusa</surname><given-names>MD</given-names></name></person-group>. <article-title>Acute kidney injury associated with cardiac surgery</article-title>. <source>Clin J Am Soc Nephrol</source>. (<year>2006</year>) <volume>1</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.00240605</pub-id><pub-id pub-id-type="pmid">17699187</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>LP</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Mu</surname><given-names>JX</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Value of urinary KIM-1 and NGAL combined with serum cys C for predicting acute kidney injury secondary to decompensated cirrhosis</article-title>. <source>Sci Rep</source>. (<year>2018</year>) <volume>8</volume>(<issue>1</issue>):<fpage>7962</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-26226-6</pub-id><pub-id pub-id-type="pmid">29784944</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Artunc</surname><given-names>F</given-names></name><name><surname>Schleicher</surname><given-names>E</given-names></name><name><surname>Weigert</surname><given-names>C</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>H&#x000e4;ring</surname><given-names>H-U</given-names></name></person-group>. <article-title>The impact of insulin resistance on the kidney and vasculature</article-title>. <source>Nat Rev Nephrol</source>. (<year>2016</year>) <volume>12</volume>(<issue>12</issue>):<fpage>721</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1038/nrneph.2016.145</pub-id><pub-id pub-id-type="pmid">27748389</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbasi</surname><given-names>F</given-names></name><name><surname>Reaven</surname><given-names>GM</given-names></name></person-group>. <article-title>Comparison of two methods using plasma triglyceride concentration as a surrogate estimate of insulin action in nondiabetic subjects: triglycerides glucose versus triglyceride/high density lipoprotein cholesterol</article-title>. <source>Metab Clin Exp</source>. (<year>2011</year>) <volume>60</volume>(<issue>12</issue>):<fpage>1673</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.metabol.2011.04.006</pub-id><pub-id pub-id-type="pmid">21632070</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simental-Mend&#x000ed;a</surname><given-names>LE</given-names></name><name><surname>Rodr&#x000ed;guez-Mor&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Guerrero-Romero</surname><given-names>F</given-names></name></person-group>. <article-title>The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects</article-title>. <source>Metab Syndr Relat Disord</source>. (<year>2008</year>) <volume>6</volume>(<issue>4</issue>):<fpage>299</fpage>&#x02013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1089/met.2008.0034</pub-id><pub-id pub-id-type="pmid">19067533</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>S-C</given-names></name><name><surname>Zhao</surname><given-names>X-H</given-names></name></person-group>. <article-title>The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST-Segment elevation acute coronary syndrome</article-title>. <source>Dis Markers</source>. (<year>2019</year>) <volume>2019</volume>(<issue>1&#x02013;11</issue>):<fpage>6891537</fpage>. <pub-id pub-id-type="doi">10.1155/2019/6891537</pub-id><pub-id pub-id-type="pmid">31281548</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name></person-group>. <article-title>Association between triglyceride-glucose index and hypertension: a meta-analysis</article-title>. <source>Front Cardiovasc Med</source>. (<year>2021</year>) <volume>8</volume>:<fpage>644035</fpage>. <pub-id pub-id-type="doi">10.3389/fcvm.2021.644035</pub-id><pub-id pub-id-type="pmid">34136539</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name></person-group>. <article-title>Association between triglyceride-glucose index and risk of incident diabetes: a secondary analysis based on a Chinese cohort study: TyG index and incident diabetes</article-title>. <source>Lipids Health Dis</source>. (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>236</fpage>. <pub-id pub-id-type="doi">10.1186/s12944-020-01403-7</pub-id><pub-id pub-id-type="pmid">33161902</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Relationship between the TyG index and diabetic kidney disease in patients with type-2 diabetes mellitus</article-title>. <source>Diabetes Metab Syndr Obes</source>. (<year>2021</year>) <volume>14</volume>:<fpage>3299</fpage>&#x02013;<lpage>06</lpage>. <pub-id pub-id-type="doi">10.2147/DMSO.S318255</pub-id><pub-id pub-id-type="pmid">34305401</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Chi</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Association between macro and microvascular damage and the triglyceride glucose index in community dwelling elderly individuals: the northern shanghai study</article-title>. <source>Cardiovasc Diabetol</source>. (<year>2019</year>) <volume>18</volume>(<issue>1</issue>):<fpage>95</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-019-0898-x</pub-id><pub-id pub-id-type="pmid">31345238</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>A high triglyceride-glucose index is associated with contrast-induced acute kidney injury in Chinese patients with type 2 diabetes mellitus</article-title>. <source>Front Endocrinol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>522883</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2020.522883</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khwaja</surname><given-names>A</given-names></name></person-group>. <article-title>KDIGO clinical practice guidelines for acute kidney injury</article-title>. <source>Nephron Clin Pract.</source> (<year>2012</year>) <volume>120</volume>:<fpage>c179</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1159/000339789</pub-id><pub-id pub-id-type="pmid">22890468</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shacham</surname><given-names>Y</given-names></name><name><surname>Gal-Oz</surname><given-names>A</given-names></name><name><surname>Leshem-Rubinow</surname><given-names>E</given-names></name><name><surname>Arbel</surname><given-names>Y</given-names></name><name><surname>Keren</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Admission glucose levels and the risk of acute kidney injury in nondiabetic ST segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention</article-title>. <source>Cardiorenal Med</source>. (<year>2015</year>) <volume>5</volume>(<issue>3</issue>):<fpage>191</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1159/000430472</pub-id><pub-id pub-id-type="pmid">26195971</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Pham</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name><name><surname>Perkins</surname><given-names>GA</given-names></name><name><surname>Ali</surname><given-names>SS</given-names></name><etal/></person-group>
<article-title>Hypoxia-inducible factor-1&#x003b1; activation improves renal oxygenation and mitochondrial function in early chronic kidney disease</article-title>. <source>Am J Physiol Renal Physiol</source>. (<year>2017</year>) <volume>313</volume>(<issue>2</issue>):<fpage>F282</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.00579.2016</pub-id><pub-id pub-id-type="pmid">28331062</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DM</given-names></name></person-group>, <collab>DCCT/EDIC Research Group</collab>. <article-title>The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview</article-title>. <source>Diabetes Care</source>. (<year>2014</year>) <volume>37</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.2337/dc13-2112</pub-id><pub-id pub-id-type="pmid">24356592</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Lyv</surname><given-names>F</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in apolipoprotein E knockout mice</article-title>. <source>Int J Mol Sci</source>. (<year>2014</year>) <volume>15</volume>(<issue>7</issue>):<fpage>11416</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.3390/ijms150711416</pub-id><pub-id pub-id-type="pmid">24972137</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorhead</surname><given-names>JF</given-names></name><name><surname>Chan</surname><given-names>MK</given-names></name><name><surname>El-Nahas</surname><given-names>M</given-names></name><name><surname>Varghese</surname><given-names>Z</given-names></name></person-group>. <article-title>Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease</article-title>. <source>Lancet</source>. (<year>1982</year>) <volume>2</volume>(<issue>8311</issue>):<fpage>1309</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(82)91513-6</pub-id><pub-id pub-id-type="pmid">6128601</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Ke</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Hypertriglyceridemia is a risk factor for acute kidney injury in the early phase of acute pancreatitis</article-title>. <source>Pancreas</source>. (<year>2014</year>) <volume>43</volume>(<issue>8</issue>):<fpage>1312</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/MPA.0000000000000180</pub-id><pub-id pub-id-type="pmid">25058883</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whaley-Connell</surname><given-names>A</given-names></name><name><surname>Sowers</surname><given-names>JR</given-names></name></person-group>. <article-title>Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity?</article-title>
<source>Cardiorenal Med</source>. (<year>2017</year>) <volume>8</volume>(<issue>1</issue>):<fpage>41</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000479801</pub-id><pub-id pub-id-type="pmid">29344025</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Positive association of triglyceride-glucose index with new-onset hypertension among adults: a national cohort study in China</article-title>. <source>Cardiovasc Diabetol</source>. (<year>2023</year>) <volume>22</volume>(<issue>1</issue>):<fpage>58</fpage>. <pub-id pub-id-type="doi">10.1186/s12933-023-01795-7</pub-id><pub-id pub-id-type="pmid">36927705</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>YM</given-names></name><name><surname>Chen</surname><given-names>WJ</given-names></name><name><surname>Deng</surname><given-names>ZL</given-names></name><name><surname>Shang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>. <article-title>Association between triglyceride-glucose index and risk of end-stage renal disease in patients with type 2 diabetes mellitus and chronic kidney disease</article-title>. <source>Front Endocrinol</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1150980</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2023.1150980</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero-Romero</surname><given-names>F</given-names></name><name><surname>Simental-Mend&#x000ed;a</surname><given-names>LE</given-names></name><name><surname>Gonz&#x000e1;lez-Ortiz</surname><given-names>M</given-names></name><name><surname>Mart&#x000ed;nez-Abundis</surname><given-names>E</given-names></name><name><surname>Ramos-Zavala</surname><given-names>MG</given-names></name><name><surname>Hern&#x000e1;ndez-Gonz&#x000e1;lez</surname><given-names>SO</given-names></name><etal/></person-group>
<article-title>The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp</article-title>. <source>Clin Endocrinol Metab</source>. (<year>2010</year>) <volume>95</volume>(<issue>7</issue>):<fpage>3347</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-0288</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Jing</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name></person-group>. <article-title>Estimate of reduced glomerular filtration rate by triglyceride-glucose index: insights from a general Chinese population</article-title>. <source>Postgrad Med</source>. (<year>2019</year>) <volume>131</volume>(<issue>4</issue>):<fpage>287</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1080/00325481.2019.1595983</pub-id><pub-id pub-id-type="pmid">30892125</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Dai</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Association between triglyceride-glucose index and worsening renal function in the elderly</article-title>. <source>Front Nutr</source>. (<year>2022</year>) <volume>9</volume>:<fpage>951564</fpage>. <pub-id pub-id-type="doi">10.3389/fnut.2022.951564</pub-id><pub-id pub-id-type="pmid">36505264</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>GI</given-names></name><name><surname>Hale</surname><given-names>LJ</given-names></name><name><surname>Eremina</surname><given-names>V</given-names></name><name><surname>Jeansson</surname><given-names>M</given-names></name><name><surname>Maezawa</surname><given-names>Y</given-names></name><name><surname>Lennon</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Insulin signaling to the glomerular podocyte is critical for normal kidney function</article-title>. <source>Cell Metab</source>. (<year>2010</year>) <volume>12</volume>(<issue>4</issue>):<fpage>329</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2010.08.015</pub-id><pub-id pub-id-type="pmid">20889126</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name></person-group>. <article-title>The perioperative hyperchloremia is associated with postoperative acute kidney injury in patients with off-pump coronary artery bypass grafting: a retrospective study</article-title>. <source>Heart Surg Forum</source>. (<year>2020</year>) <volume>23</volume>(<issue>6</issue>):<fpage>E902</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1532/hsf.3443</pub-id><pub-id pub-id-type="pmid">33399532</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumbert</surname><given-names>SD</given-names></name><name><surname>Kork</surname><given-names>F</given-names></name><name><surname>Jackson</surname><given-names>ML</given-names></name><name><surname>Vanga</surname><given-names>N</given-names></name><name><surname>Ghebremichael</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name><etal/></person-group>
<article-title>Perioperative acute kidney injury</article-title>. <source>Anesthesiology</source>. (<year>2020</year>) <volume>132</volume>:<fpage>180</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0000000000002968</pub-id><pub-id pub-id-type="pmid">31687986</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahbazi</surname><given-names>S</given-names></name><name><surname>Alishahi</surname><given-names>P</given-names></name><name><surname>Asadpour</surname><given-names>E</given-names></name></person-group>. <article-title>Evaluation of the effect of aminophylline in reducing the incidence of acute kidney injury after cardiac surgery</article-title>. <source>Anesth Pain Med</source>. (<year>2017</year>) <volume>7</volume>(<issue>4</issue>):<fpage>e21740</fpage>. <pub-id pub-id-type="doi">10.5812/aapm.21740</pub-id><pub-id pub-id-type="pmid">29696106</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Dent</surname><given-names>C</given-names></name><name><surname>Tarabishi</surname><given-names>R</given-names></name><name><surname>Mitsnefes</surname><given-names>MM</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery</article-title>. <source>Lancet</source>. (<year>2005</year>) <volume>365</volume>:<fpage>1231</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(05)74811-X</pub-id><pub-id pub-id-type="pmid">15811456</pub-id>
</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forni</surname><given-names>LG</given-names></name><name><surname>Darmon</surname><given-names>M</given-names></name><name><surname>Ostermann</surname><given-names>M</given-names></name><name><surname>Oudemans-van Straaten</surname><given-names>HM</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V</given-names></name><name><surname>Prowle</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>Renal recovery after acute kidney injury</article-title>. <source>Intensive Care Med</source>. (<year>2017</year>) <volume>43</volume>(<issue>6</issue>):<fpage>855</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-017-4809-x</pub-id><pub-id pub-id-type="pmid">28466146</pub-id>
</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S-M</given-names></name></person-group>. <article-title>Acute kidney injury after cardiac surgery: risk factors and novel biomarkers</article-title>. <source>Braz J Cardiovasc Surg</source>. (<year>2019</year>) <volume>34</volume>(<issue>3</issue>):<fpage>352</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.21470/1678-9741-2018-0212</pub-id><pub-id pub-id-type="pmid">31310475</pub-id>
</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanase</surname><given-names>DM</given-names></name><name><surname>Gosav</surname><given-names>EM</given-names></name><name><surname>Radu</surname><given-names>S</given-names></name><name><surname>Costea</surname><given-names>CF</given-names></name><name><surname>Ciocoiu</surname><given-names>M</given-names></name><name><surname>Carauleanu</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The predictive role of the biomarker kidney molecule-1 (KIM-1) in acute kidney injury (AKI) cisplatin-induced nephrotoxicity</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>(<issue>20</issue>):<fpage>5238</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20205238</pub-id><pub-id pub-id-type="pmid">31652595</pub-id>
</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Association between the triglyceride-glucose Index and outcomes of nonalcoholic fatty liver disease: a large-scale health management cohort study</article-title>. <source>Diabetes Metab Syndr Obes</source>. (<year>2021</year>) <volume>14</volume>:<fpage>2829</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.2147/DMSO.S316864</pub-id><pub-id pub-id-type="pmid">34188506</pub-id>
</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>M-S</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Chung</surname><given-names>GE</given-names></name><name><surname>Kang</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><etal/></person-group>
<article-title>Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease</article-title>. <source>Clin Mol Hepatol</source>. (<year>2012</year>) <volume>18</volume>(<issue>4</issue>):<fpage>383</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.3350/cmh.2012.18.4.383</pub-id><pub-id pub-id-type="pmid">23323254</pub-id>
</mixed-citation></ref></ref-list></back></article>